Publication:
Immunosuppressive treatment in C3 glomerulopathy: Is it really effective?

dc.contributor.authorÇalışkan, Yaşar
dc.contributor.authorTorun, Ege Sinan
dc.contributor.authorTiryaki, Tarık Onur
dc.contributor.authorÖzlük, Yasemin
dc.contributor.authorAkgül, Sebahat Usta
dc.contributor.authorTemürhan, Sonay
dc.contributor.authorÖztop, Nida
dc.contributor.authorKılıçaslan, Işın
dc.contributor.authorSever, Mehmet Şükrü
dc.contributor.buuauthorOruç, Ayşegül
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentİç Hastalıkları Ana Bilim Dalı
dc.contributor.departmentNefroloji Ana Bilim Dalı
dc.contributor.researcheridAAH-4002-2021
dc.contributor.scopusid55133912100
dc.date.accessioned2022-12-26T12:48:13Z
dc.date.available2022-12-26T12:48:13Z
dc.date.issued2017-06-17
dc.description.abstractBackground: C3 glomerulopathy (C3GP) is a recently identified and described disease that has a high risk of progressing into end-stage renal disease. We aimed to evaluate the effects of various immunosuppressive regimens on C3GP progression because there are conflicting data on the treatment modalities. Methods: In this retrospective study of 66 patients with C3GP, 27 patients received mycophenolate mofetil (MMF)-based treatment, 23 received non-MMF-based treatment (prednisolone or cyclophosphamide), and 16 received conservative care. The study groups were compared with each other with specific focus on primary outcomes defined as (1) kidney failure and (2) estimated glomerular filtration rate (eGFR) decline >= 50% from the baseline value. Results: Overall, 17 (25.8%) patients reached the primary outcome after a median period of 28 months. The number of patients who reached the primary outcome were similar among the study groups (MMF-based: 8/27 [29.6%], non-MMF-based: 4/23 [17.4%], and conservative care: 5/16 [31.3%], p = 0.520). In the Cox regression analysis, age (HR 0.912, p = 0.006), eGFR (HR 0.945, p = 0.001), and proteinuria levels (HR 1.418, p = 0.015) at the time of biopsy, percentage of crescentic (HR 1.035, p = 0.001) and sclerotic glomeruli (HR 1.041, p = 0.006), severity of interstitial fibrosis (HR 1.981, p = 0.048), as well as no remission of proteinuria (HR 2.418, p = 0.002) predicted the primary outcome. Conclusion: Although patients receiving immunosuppressive treatments had higher proteinuria and lower serum albumin at baseline, there were no differences between these patients and those receiving conservative care alone in proteinuria remission or in the decline of renal function. Younger age, higher proteinuria, lower eGFR, and the presence of crescentic and sclerotic glomeruli, severity of interstitial fibrosis, and no remission of proteinuria predicted the progression of kidney disease.
dc.identifier.citationÇalışkan, Y. vd. (2017). ''Immunosuppressive treatment in C3 glomerulopathy: Is it really effective?''. American Journal of Nephrology, 46(2), 96-107.
dc.identifier.endpage107
dc.identifier.issn0250-8095
dc.identifier.issue2
dc.identifier.pubmed28700996
dc.identifier.scopus2-s2.0-85023751797
dc.identifier.startpage96
dc.identifier.urihttps://doi.org/10.1159/000479012
dc.identifier.urihttps://www.karger.com/Article/FullText/479012
dc.identifier.uri1421-9670
dc.identifier.urihttp://hdl.handle.net/11452/30095
dc.identifier.volume46
dc.identifier.wos000408371900002
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherKarger
dc.relation.collaborationYurt içi
dc.relation.journalAmerican Journal of Nephrology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectUrology & nephrology
dc.subjectC3 glomerulopathy
dc.subjectComplement system
dc.subjectEnd-stage renal disease
dc.subjectProteinuria
dc.subjectDense deposit disease
dc.subjectHemolytic-uremic syndrome
dc.subjectComplement abnormalities
dc.subjectEculizumab
dc.subjectGlomerulonephritis
dc.subjectAdult
dc.subject.emtreeAlbumin
dc.subject.emtreeComplement component C1q
dc.subject.emtreeComplement component C3
dc.subject.emtreeCyclophosphamide
dc.subject.emtreeImmunoglobulin A
dc.subject.emtreeImmunoglobulin G
dc.subject.emtreeImmunoglobulin M
dc.subject.emtreeMycophenolate mofetil
dc.subject.emtreePrednisolone
dc.subject.emtreeAntiinflammatory agent
dc.subject.emtreeC3 protein, human
dc.subject.emtreeComplement component C3
dc.subject.emtreeCreatinine
dc.subject.emtreeImmunosuppressive agent
dc.subject.emtreeAdult
dc.subject.emtreeAnemia
dc.subject.emtreeArticle
dc.subject.emtreeBladder disease
dc.subject.emtreeBlood cell count
dc.subject.emtreeClinical outcome
dc.subject.emtreeConservative treatment
dc.subject.emtreeControlled study
dc.subject.emtreeCreatinine blood level
dc.subject.emtreeDiarrhea
dc.subject.emtreeDrug dose reduction
dc.subject.emtreeDrug megadose
dc.subject.emtreeDrug withdrawal
dc.subject.emtreeEstimated glomerular filtration rate
dc.subject.emtreeFemale
dc.subject.emtreeFibrosing alveolitis
dc.subject.emtreeGender
dc.subject.emtreeGlomerulopathy
dc.subject.emtreeHematuria
dc.subject.emtreeHistopathology
dc.subject.emtreeHuman
dc.subject.emtreeHypocomplementemia
dc.subject.emtreeImmunofluorescence
dc.subject.emtreeImmunofluorescence test
dc.subject.emtreeImmunosuppressive treatment
dc.subject.emtreeKidney biopsy
dc.subject.emtreeKidney failure
dc.subject.emtreeLeukopenia
dc.subject.emtreeLow drug dose
dc.subject.emtreeMajor clinical study
dc.subject.emtreeMale
dc.subject.emtreeMembranoproliferative glomerulonephritis
dc.subject.emtreeNausea
dc.subject.emtreeNephrotic syndrome
dc.subject.emtreePneumonia
dc.subject.emtreePriority journal
dc.subject.emtreeProteinuria
dc.subject.emtreeRemission
dc.subject.emtreeRetrospective study
dc.subject.emtreeSanger sequencin
dc.subject.emtreeThrombocytopenia
dc.subject.emtreeAge
dc.subject.emtreeBiopsy
dc.subject.emtreeBlood
dc.subject.emtreeChronic kidney failure
dc.subject.emtreeComparative study
dc.subject.emtreeDisease exacerbation
dc.subject.emtreeFibrosis
dc.subject.emtreeGlomerulonephritis
dc.subject.emtreeGlomerulus
dc.subject.emtreeGlomerulus filtration rate
dc.subject.emtreeMetabolism
dc.subject.emtreeMiddle aged
dc.subject.emtreePathology
dc.subject.emtreeProteinuria
dc.subject.emtreeRisk factor
dc.subject.emtreeTreatment outcome
dc.subject.emtreeUrine
dc.subject.emtreeYoung adult
dc.subject.meshAdult
dc.subject.meshAge factors
dc.subject.meshAnti-Inflammatory agents
dc.subject.meshBiopsy
dc.subject.meshComplement C3
dc.subject.meshCreatinine
dc.subject.meshDisease progression
dc.subject.meshFemale
dc.subject.meshFibrosis
dc.subject.meshGlomerular filtration rate
dc.subject.meshGlomerulonephritis
dc.subject.meshHumans
dc.subject.meshImmunosuppressive agents
dc.subject.meshKidney failure, chronic
dc.subject.meshKidney glomerulus
dc.subject.meshMale
dc.subject.meshMiddle aged
dc.subject.meshProteinuria
dc.subject.meshRetrospective studies
dc.subject.meshRisk factors
dc.subject.meshTreatment outcome
dc.subject.meshYoung adult
dc.subject.scopusImmunoglobulin A Nephropathy; Proteinuria; Kidney Diseases
dc.subject.wosUrology & nephrology
dc.titleImmunosuppressive treatment in C3 glomerulopathy: Is it really effective?
dc.typeArticle
dc.wos.quartileQ2
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/İç Hastalıkları Ana Bilim Dalı/Nefroloji Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: